F10 and atrial fibrillation: The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) randomized controlled clinical trial showed that compared with well-managed warfarin, once-daily edoxaban showed a similar efficacy for stroke or systemic embolic event (SEE) prevention, with lower rates of bleeding and cardiovascular death [5].